Zachary Klaassen: Hi, my name is Zach Klaassen. I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. We're in Chicago for ASCO 2025. I'm delighted to be joined by Dr. Ray Manneh who is a medical oncologist in Colombia. Ray, thanks for joining us on today.

Ray Manneh Kopp: Thank you, Zach. Real pleasure to be here. I'm really honored that you invited me, and I would like to thank all the team.

Zachary Klaassen: Now, we're delighted to have you. You guys have basically a real-world analysis of prostate cancer treatment in Colombia. We have a lot of real-world evidence in the United States, so really was great to read through your work and the work you presented this weekend. So just talk to us before we get into that, a little bit about health in Colombia, maybe how prostate cancer patients are referred and screened.

Ray Manneh Kopp: The healthcare system in Colombia has a really high percentage of coverage for the population. We have divided the system in two small systems-- one for the people who don't work or don't contribute to the system and another one for the workers, the ones that contribute to the system. So the access for both parts is assumably equal. But it actually is really different. The people from the non-worker system or the subsidiary system have less access to technologies, have less access to PSA testing, and arrive later in their disease course, and people from the workers side, the contributed system have better access.

Zachary Klaassen: OK, excellent. In that context, so tell us about the study design for the work you presented this weekend?

Ray Manneh Kopp: It's a retrospective multicenter analysis that we included main facilities from the main cities from Barranquilla, Bogota, Cali, Medellin, and Valledupar. And we included almost 400 patients. This is the report of the first 130 patients that we gathered.

We have a lack of information in our region and in our country, so it's really important to characterize the population to describe our disease characteristics, the treatment patterns, the healthcare resource utilization. So it's a really big issue for us to be able to describe this.

Zachary Klaassen: And great job putting it together. I mean, maybe just give us some of the highlights of the demographics and some of the treatment patterns you guys pulled out of your study.

Ray Manneh Kopp: OK, the median age is 78 years old. It's a little bit lower than in the first world. We have a high rate of de novo metastatic patients, is 55% of the patients in this cohort are de novo metastatic. We have an ARPI intensification of about 10% and docetaxel intensification of about 30%.

Zachary Klaassen: So more docetaxel than in some countries.

Ray Manneh Kopp: More docetaxel. And I think that's because we included patients from January 2017 until June 2023. So we are seeing patients with metastatic hormone-sensitive setting before that time. So we are analyzing in a retrospective way our data.

Zachary Klaassen: Yeah, no, it makes sense. One thing I thought interesting, we have to do a better job in this country, too, with genomic testing. And I noticed yours was about one-third. Maybe speak to maybe why that is and maybe ways to improve it in Colombia.

Ray Manneh Kopp: We analyzed the rate of HRR and MSI testing, and we found that almost 30% of the population was tested. And I think that it's because also a lack of access to the testing that we had before. Nowadays, we have more access to these HRR testing.

Zachary Klaassen: Excellent.

Ray Manneh Kopp: Interestingly, we saw an overall survival advantage in men that were tested. It's a big difference. You can see it in the-- You can see the curves in the poster are 50 months against 39 months. It's a big difference. We may have bias because maybe patients that live longer have the more chance to be tested, but--

Zachary Klaassen: Maybe better access to care, too.

Ray Manneh Kopp: Better access to care, yeah.

Zachary Klaassen: That's great. Anything we haven't hit on that you want to share with our audience? Maybe a couple of concluding statements.

Ray Manneh Kopp: It's really important for Latin America to be on stage. We have lots of patients. We are growing as a GU community. We are gathering together with urologists. We are working together with them. And it's really important for us to share our data.

Zachary Klaassen: No, it's great. And South America is such a huge supporter of UroToday. So it's great to have you on for that reason, but also to talk about your data as well. So thank you for joining us, Ray.

Ray Manneh Kopp: Thank you, Zach. Thank you.